Journal of Pharmacology and Pharmacotherapeutics, Ahead of Print.
BackgroundUbrogepant is a first-generation gepant-class drug approved for the oral treatment of migraine.PurposeThis work aimed at developing an intranasal gel consisting of ubrogepant nanoparticles (NPs), with the aim of improving its therapeutic …